Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 8/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11476098 | 0.84 | KMT2A (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL1734681 | 0.81 | NAAA (0.48) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL20816343 | 0.80 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL28697224 | 0.80 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL2229952 | 0.80 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL14057227 | 0.80 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL755683 | 0.79 | DGAT1 (0.37) | USP2LMNAGAA | |
| SCHEMBL5878909 | 0.78 | MAPT (0.45) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL7783336 | 0.78 | MAPT (0.45) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL9376141 | 0.78 | MAPT (0.45) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052545-A1 | COMPOSITIONS AND METHODS OF THEIR USE | CHEMIC LABORATORIES, LLC | 2021-02-25 | — | — | US | disclosed |
| US-20210045993-A1 | COSMETIC COMPOSITIONS | ELEBLEND LLC | 2021-02-18 | — | — | US | disclosed |
| US-20190328884-A1 | COMPOSITIONS AND METHODS OF THEIR USE | CHEMIC LABORATORIES, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20140357600-A1 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS | CHEMIC LABORATORIES INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20130089577-A1 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS | CHEMSMART, LLC | 2013-04-11 | — | — | US | disclosed |
| WO-2011113000-A1 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS | CHEMSMART, LLC (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052545-A1 | COMPOSITIONS AND METHODS OF THEIR USE | CNR2, CNR1, SGMS1 | MEN1 1334/4885MAPT 667/4885KMT2A 1273/4885 |
| US-20130089577-A1 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS | LIPA, LIPC, LIPG | MEN1 4285/4885MAPT 1384/4885KMT2A 4325/4885 |
| US-20140357600-A1 | NOVEL ESTER CONTAINING COMPOSITIONS AND METHODS | LIPA, LIPC, LIPG | MEN1 4285/4885MAPT 1384/4885KMT2A 4325/4885 |
| US-20210045993-A1 | COSMETIC COMPOSITIONS | CUTA, SUCLG1, ASAH2 | MEN1 317/4885MAPT 762/4885KMT2A 1636/4885 |
| US-20190328884-A1 | COMPOSITIONS AND METHODS OF THEIR USE | SGMS2, SGMS1, LIPA | MEN1 635/4885MAPT 389/4885KMT2A 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.